IP Library Granted Patent US 10,647,740
Granted Patent B2
US 10,647,740 · App. 15/850,028 · Granted May 12, 2020

Multisignal labeling reagents and processes and uses therefor

Inventors: Jack Coleman (East Northport, NY); Elazar Rabbani (New York, NY); Jannis Stavrianopoulos (Bay Shore, NY); Praveen Pande (Holbrook, NY)
Assignee: Enzo Life Science, Inc.
C07H21/00C07D219/08C07D405/14C07D491/22C07H21/04C09B11/00C09B11/08C09B11/24C09B57/02C12Q1/68C12Q1/6818G01N33/533G01N33/582
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,647,740
App. No.
15/850,028
Granted
May 12, 2020
Kind
B2
Abstract

Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA supramolecular binding molecule noncovalently bound to the oligomer; and (iii) a first reactive group or a first partner of a first binding pair covalently bound to the oligomer. Additionally provided are methods of producing multisignal labeling reagents.

Claims (26)

1. A method of producing a multisignal labeling reagent, the method comprising

(a) obtaining

(i) a primer comprising an oligonucleotide;

(ii) a template comprising a nucleic acid comprising a first sequence that is complementary to the oligonucleotide and a second sequence that extends in the 5′ direction from the first sequence;

(iii) a polymerase capable of extending the oligonucleotide along the template nucleic acid when the template nucleic acid is hybridized to the oligonucleotide at the first sequence;

(iv) nucleotide triphosphates (NTPs) or analogs thereof that are capable of being incorporated into the extended oligonucleotide, wherein at least one of the NTPs or analogs comprises a non-radioactive detectable label, a second reactive group or a first partner of a second binding pair; and

(v) a polymer capable of binding to more than one of the extended oligonucleotide, wherein the polymer comprises a first reactive group or a first partner of a first binding pair;

(b) combining the primer, template, polymerase and NTPs or analogs under conditions such that the oligonucleotide hybridizes to the first sequence and is extended along the second sequence, where the extended oligonucleotide comprises at least two NTPs or analogs incorporated therein that comprise a non-radioactive detectable label, a second reactive group or a first partner of a second binding pair; and

(c) combining the extended oligonucleotide with the polymer under conditions such that at least two of the extended oligonucleotides bind to the polymer,

wherein,

(A) if at least one of the at least two NTPs or analogs incorporated into the extended oligonucleotide comprises a second reactive group, the method further comprises combining the extended oligonucleotide with a first compound comprising a non-radioactive detectable label covalently linked to a moiety capable of reacting with the second reactive group such that the label is covalently linked to the extended primer, and

(B) if at least one of the at least two NTPs or analogs incorporated into the extended oligonucleotide comprises a first partner of the second binding pair, the method further comprises combining the extended primer with a second compound comprising the non- radioactive detectable label covalently linked to a second binding partner of the second binding pair.

2. The method of claim 1 , wherein the non-radioactive detectable labels are fluorophores, phosphorescent moieties, chemiluminescent moieties, chelating moieties, electron dense moieties, magnetic moieties, or energy transfer moieties.

3. The method of claim 1 , wherein the non-radioactive detectable labels are fluorophores.

4. The method of claim 1 , wherein the two NTPs or analogs incorporated into the extended oligonucleotide are each labeled with a reactive group.

5. The method of claim 4 , wherein each reactive group is joined to the NTPs by a linker arm.

6. The method of claim 1 , wherein the NTP or NTP analogs are each labeled with a non-radioactive detectable label.

7. The method of claim 3 , wherein the NTP or NTP analogs are each labeled with a first binding partner of a second binding pair.

8. The method of claim 7 , wherein the first binding partner of the second binding pair is a biotin.

9. The method of claim 7 , wherein each first binding partner of the second binding pair is connected to the NTPs by a linker arm.

10. The method of claim 1 , wherein the multisignal labeling reagent further comprises a non-inherent charged group that increases the aqueous solubility of the reagent.

11. The method of claim 1 , wherein the polymer comprises a first partner of a first binding pair.

12. The method of claim 11 , wherein the first binding pair is a ligand/receptor, a hormone/receptor, biotin/avidin, biotin/streptavidin or an antigen/antibody.

13. The method of claim 11 , wherein the first partner of the first binding pair is biotin.

14. The method of claim 12 , wherein the polymer is a polynucleotide comprising more than one region that is complementary to a portion of the extended oligonucleotide.

15. The method of claim 1 , further comprising combining the multisignal labeling reagent with a target molecule such that the multisignal labeling reagent is bound to the target by the first reactive group or the first partner of the first binding pair.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2018
From: COLEMAN, JACK; RABBANI, ELAZAR; STAVRIANOPOULOS, JANNIS; PANDE, PRAVEEN
To: ENZO LIFE SCIENCES, INC.
Reel/Frame 044762/0521 →
Continuity (5)
Continuation 14844468 · Sep 3, 2015
Division 13065101 · Mar 14, 2011
Continuation In Part 12399393 · Mar 6, 2009
Division 10407818 · Apr 3, 2003
Related Publication 20180127456A1 · May 10, 2018